Recently, our group has developed several carrier-free strategies for selectively delivering bioactive proteins such as green fluorescent protein and ß-galactosidase, as well as small molecules, into tumour cells by conjugating them with tumour-specific binding peptides against tumour biomarkers such as integrin and EGFR [43,44,45,46,47]. This evidence concerns the gene EGFR and neoplasm.